Saturday, April 19, 2014

Isotechnika officially changes name to Aurinia Pharma

Isotechnika officially changes name to Aurinia Pharma

October 22, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX-V:ISA) has officially changed its name to Aurinia Pharmaceuticals and its common shares will be posted for trading on a 50:1 consolidated basis on the TSX Venture Exchange at the opening tomorrow under the trading symbol, AUP. The consolidation will result in 12,373,589 shares outstanding. “In many respects, the new Aurinia just […]

Isotechnika, Aurinia complete merger, financing

Isotechnika, Aurinia complete merger, financing

September 23, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals have completed their merger and will operate under the name, Aurinia Pharmaceuticals. The transaction was approved by shareholders on Aug. 15. In connection with the merger, the company has completed, subject to regulatory approval, a private placement of 133,333,332 units, consisting of one common share and one half […]

Isotechnika holders okay merger with Aurinia

Isotechnika holders okay merger with Aurinia

August 16, 2013 by · Leave a Comment 

Tweet Shareholders of Isotechnika Pharma (TSX:ISA) have approved a merger with closely-held Aurinia Pharmaceuticals to create a clinical-stage pharmaceutical company focused on the global nephrology market. The plan of arrangement will be affected by an exchange of Isotechnika shares for securities of Aurinia, resulting in a 65-35 post-merger ownership split between the shareholders of Isotechnika […]

Isotechnika sets meeting to vote on merger for Aug. 15

Isotechnika sets meeting to vote on merger for Aug. 15

July 25, 2013 by · Leave a Comment 

Tweet A meeting of Isotechnika Pharma (TSX:ISA) shareholders to consider a proposed merger with closely held Aurinia Pharmaceuticals will be held on Aug. 15. The boards of Isotechnika and Aurinia firmly support the proposed merger, which is designed to create a premier clinical stage pharmaceutical company focused on the global nephrology market. The merger is […]

Isotechnika further updates merger and financing plans

Isotechnika further updates merger and financing plans

June 27, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and privately-held Aurinia Pharmaceuticals have issued a further update about their proposed merger to create a premiere clinical-stage pharmaceutical company focused on the global nephrology market. Under the merger accord, Isotechnika will acquire 100% of Aurinia in a stock swap, resulting in a 65-35 post-merger ownership split between Isotechnika and Aurinia, […]

Isotechnika gets more funding for NICAM program

Isotechnika gets more funding for NICAM program

June 18, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its non-immunosuppressive cyclophilin antagonist molecules (NICAM) program. NRC-IRAP continues to play an instrumental role in networking the NICAM program with key global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including […]

Isotechnika updates investors on planned merger with Aurinia

Isotechnika updates investors on planned merger with Aurinia

April 17, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have updated investors on their proposed merger to create a global nephrology company. The companies have now executed a definitive tripartite agreement with ILJIN Life Science. Subject to the successful completion of the proposed merger, the combined company will re-acquire full rights to voclosporin for autoimmune indications, […]

Takeda deal in lupus highlights Isotechnika-Aurinia merger potential

Takeda deal in lupus highlights Isotechnika-Aurinia merger potential

February 28, 2013 by · Leave a Comment 

Tweet A $255-million development partnership between Takeda Pharmaceutical and Resolve Therapeutics to develop compounds for the treatment of lupus and other autoimmune diseases highlights the potential of a merger between Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals to develop Isotechnika’s voclosporin drug for lupus nephritis. Resolve’s lead compound, RSLV-132, will begin clinical development later this year. […]

Isotechnika merger with Aurinia to create nephrology leader

Isotechnika merger with Aurinia to create nephrology leader

February 5, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have signed a binding term sheet to merge and create a premier clinical-stage pharmaceutical company focused on the global nephrology market. Aurinia is a spin-out from Vifor Pharma, the pharmaceutical arm of Swiss-based Galenica Group. Aurinia’s current leadership team is comprised primarily of former senior managers, directors […]

ILJIN withdraws damage claims against Isotechnika

ILJIN withdraws damage claims against Isotechnika

January 15, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) announced that ILJIN Life Sciences of South Korea has formally notified Isotechnika and the arbitral tribunal that it has withdrawn all claims for damages in the parties’ pending arbitration arising from a development, distribution and license agreement. As previously reported, the agreement was declared to be in “full force and effect” […]

Next Page »

Google+